Experimental Pyoderma Gangrenosum Drug Could Impact Crohn’s, Colitis Patients
News
XOMA Corporation, a company dedicated to developing antibody-based therapeutics, has begun patient enrollment for a pivotal phase III study of gevokizumab for the treatment of active pyoderma gangrenous (PG), a rare neutrophilic dermatosis of expanding necrotic ... Read more